You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter to the editor
Effects of omalizumab in Aspergillus-associated airway disease

https://doi.org/10.1136/thx.2010.153312

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding LAPL, MCV and LB have received payment from Novartis Farmaceútica for lectures, consultancy and support for travelling to meetings. AP has received support from Novartis Farmaceútica for lectures and MR for travelling to meetings. JG, MM, OA, PA, CF, CG and AP-P have no conflicts of interest.

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.